Phase 2 Chronic Kidney Disease Trial, Recruiting (NCT07268638)

Phase 2 Chronic Kidney Disease Trial, Recruiting NCT07268638 Sponsor: Akebia Therapeutics Condition: Chronic Kidney Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07268638 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Chronic Kidney Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Your urine protein levels must be at a certain elevated level, measured by a specific urine test called UPCR, showing a result of 1 or higher (confirm with trial site).
You must already be taking the highest dose of a certain type of blood pressure/kidney-protecting medication (called an ACE inhibitor or ARB) that you can tolerate, as decided by the lead doctor, within 1 month of signing up.
Your kidneys must be functioning at a minimum level, measured by a blood test called eGFR, with a result of 25 or above.
You must have had a kidney biopsy within the last 3 years that shows a condition called FSGS, or you must have a confirmed genetic change linked to FSGS.

Who may not be able to join:

People whose kidney biopsy showed a specific type of FSGS called "collapsing FSGS."
People who have sickle cell disease.
People with poorly controlled blood sugar levels, either shown by a blood test called HbA1c being above 8%, or a non-fasting blood sugar reading above 180 mg/dL.
People with high blood pressure that is not well controlled, meaning readings of 160/100 or higher.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 13 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 16178446128

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07268638

Sponsor: Akebia Therapeutics

Phase: Phase 2

Status: Recruiting

Condition: Chronic Kidney Disease

Trial contact: 16178446128

More information: https://clinicaltrials.gov/study/NCT07268638

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Your urine protein levels must be at a certain elevated level, measured by a specific urine test called UPCR, showing a result of 1 or higher (confirm with trial site).
You must already be taking the highest dose of a certain type of blood pressure/kidney-protecting medication (called an ACE inhibitor or ARB) that you can tolerate, as decided by the lead doctor, within 1 month of signing up.
Your kidneys must be functioning at a minimum level, measured by a blood test called eGFR, with a result of 25 or above.
You must have had a kidney biopsy within the last 3 years that shows a condition called FSGS, or you must have a confirmed genetic change linked to FSGS.

Who may not be able to join:

People whose kidney biopsy showed a specific type of FSGS called "collapsing FSGS."
People who have sickle cell disease.
People with poorly controlled blood sugar levels, either shown by a blood test called HbA1c being above 8%, or a non-fasting blood sugar reading above 180 mg/dL.
People with high blood pressure that is not well controlled, meaning readings of 160/100 or higher.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Akebia Therapeutics

Registry

ClinicalTrials.gov

Start date

3 December 2025

Est. completion

1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from Baseline in urine protein-to-creatinine ratio (UPCR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov